Abstract
The next few years may show that when the novel therapeutics reviewed in this article are used in thoughtful combinations, a new standard of care for the treatment of advanced melanoma will emerge. As more understanding is gained on the different signaling pathways for tumor cell growth and mechanisms of action of the different classes of drugs, the ability to identify different subsets of patients with differentially dysregulated oncogenic signaling pathways may allow for more individualized treatments of advanced melanoma in the near future, which will ultimately translate into improved survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 517-524 |
| Number of pages | 8 |
| Journal | Dermatologic clinics |
| Volume | 30 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 1 2012 |
Keywords
- Immunotherapy
- Metastatic melanoma
- Signaling pathways
- Targeted therapies
ASJC Scopus subject areas
- Dermatology
Fingerprint Dive into the research topics of 'Targeted Therapies for Metastatic Melanoma'. Together they form a unique fingerprint.
Cite this
Chandra, S., & Pavlick, A. C. (2012). Targeted Therapies for Metastatic Melanoma. Dermatologic clinics, 30(3), 517-524. https://doi.org/10.1016/j.det.2012.05.001